|
 Neuland Laboratories, a global contract development and manufacturing organization (CDMO) specialising in complex APIs, has announced a leadership change with Saharsh Davuluri to assume the role of chief executive officer and managing director, effective immediately, as the company moves into its next stage of CDMO growth.
Saharsh has been with the company for over 18 years and will position the CDMO as a premier global API process development and commercial manufacturing specialist. He succeeds Sucheth Davuluri, who has played a key role in the company’s transformation towards a CDMO-focused business model and will now assume the role of executive vice chairman of the company.
In the press communique, the company said Saharsh has led Neuland’s transformation into a new chemical entity (NCE)-focused drug substance CDMO. In recent years, the company has secured a growing number of commercial manufacturing contracts with global innovator companies, reflecting rising demand for its strengths in process chemistry, scale-up, and reliable commercial supply.
“It’s an incredibly exciting time for the wider CDMO sector, and for Neuland in particular, as global innovators increasingly come to us with their most complex chemistries and scale-up challenges. But we have not rested on these successes, and will now be looking to further accelerate this growth transformation over the next five years. We have already committed to a four-phase expansion of commercial peptide capacity and are also doubling our process development capabilities,” said Davuluri.
The CDMO operates three US FDA-inspected manufacturing facilities and a 40,000 sq. ft. R&D facility, with 1,218 KL of installed capacity and over 20 commercial contracts across APIs and intermediates. The company’s recent growth has been supported by its ability to accelerate development timelines through parallel development strategies, while maintaining a strong regulatory track record across 18 US FDA inspections
“We see immediate opportunities for commercial contract growth, particularly in areas such as peptides, but our CDMO investment approach is built around the innovation pipelines of our customers. Therefore, we continue to structure our teams and capabilities to meet the evolving development needs of our partners. Our ambition is to become one of the world’s top five API-focused CDMOs over the next decade,” said Saharsh.
|